Related content

Editorial: what is the role of antiandrogen therapy in the treatment of prostate cancer?

By Payne Heather  

Journal of Cancer Research and Clinical Oncology, Vol. 132, Iss. 1, 2006-08 ,pp. : 1-6

Springer Publishing Company

Access to resources Recommend Favorite

PSA Response to Secondary Androgen Deprivation Following Failed Treatment of Metastatic Prostate Cancer with the Antiandrogen Casodex

By Fabozzi S.J.   Kolm P.   Schellhammer P.F.  

Urologic Oncology: Seminars and Original Investigations, Vol. 1, Iss. 2, 1995-03 ,pp. : 64-66

Elsevier

Access to resources Recommend Favorite

What's new in the treatment of advanced prostate cancer?

By Sternberg C.N.  

European Journal of Cancer, Vol. 39, Iss. 2, 2003-01 ,pp. : 136-146

Elsevier

Access to resources Recommend Favorite

The role of enzalutamide in the treatment of castration-resistant prostate cancer

By Rawlinson Alex   Mohammed Aza   Miller Marek   Kunkler Roger  

Future Oncology, Vol. 8, Iss. 9, 2012-09 ,pp. : 1073-1081

Future Medicine

Access to resources Recommend Favorite

Antiandrogen treatments in locally advanced prostate cancer: are they all the same?

By Gillatt David  

Journal of Cancer Research and Clinical Oncology, Vol. 132, Iss. 13, 2006-08 ,pp. : 17-26

Springer Publishing Company

Access to resources Recommend Favorite